Back to Search
Start Over
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial
- Source :
- The Lancet HIV; April 2023, Vol. 10 Issue: 4 pe230-e243, 14p
- Publication Year :
- 2023
-
Abstract
- Young women in sub-Saharan Africa continue to bear a high burden of HIV infection. Combination anti-HIV monoclonal antibodies are a potential HIV prevention technology that could overcome adherence challenges of daily oral pre-exposure prophylaxis. In this phase 1 clinical trial we aimed to determine the safety and pharmacokinetic profile of the broadly neutralising monoclonal antibody CAP256V2LS.
Details
- Language :
- English
- ISSN :
- 24054704 and 23523018
- Volume :
- 10
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- The Lancet HIV
- Publication Type :
- Periodical
- Accession number :
- ejs62666827
- Full Text :
- https://doi.org/10.1016/S2352-3018(23)00003-6